Hatteras Venture Partners

Hatteras Venture Partners invests in seed and early-stage companies across the healthcare continuum, including sectors such as biotechnology, medical devices, diagnostics, and health technology. The firm emphasizes opportunities in regions that are research-driven but undercapitalized, particularly in North Carolina and the Southeastern United States. Their investment strategy is centered on identifying high-quality science and teams with the potential for significant impact on patient care.

Investment stages include pre-seed, seed, seed-plus, and Series A, with check sizes typically ranging from $500,000 to $5 million. Hatteras seeks to identify disruptive healthcare opportunities that can lead to substantial advancements in patient care and health outcomes.

Hatteras Venture Partners has invested in over 100 portfolio companies, showcasing a diverse range of innovations in healthcare. Notable portfolio companies include:

• 410 Medical: Develops innovative resuscitation technologies for emergency and critical care.
• Aer Therapeutics: A clinical-stage biopharmaceutical company focused on inhaled therapies for chronic lung diseases.
• Atsena Therapeutics: A clinical-stage gene therapy company targeting inherited retinal diseases.
• Cardiosense: Combines wearable sensors with AI to detect early signs of cardiac disease.
• G1 Therapeutics, Inc.: A commercial-stage biopharmaceutical company that went public in May 2017.
• HistoSonics, Inc.: Developed histotripsy technology for non-invasive tumor destruction, recently acquired for $2.25 billion.
• Kymera Therapeutics, Inc.: Focuses on targeted protein degradation, publicly traded with a market cap exceeding $3 billion.
• Jumo Health, Inc.: A leader in health education for clinical trials, acquired in 2024.
• Iris Healthcare, Inc.: Provides advanced care planning for end-of-life patients, acquired by Aledade in 2023.
• Asthmatx, Inc.: Developed a medical device for asthma treatment, acquired by Boston Scientific.

Clay Thorp — General Partner, co-leads investments and has extensive experience in healthcare venture capital.

John Crumpler — General Partner, co-leads investments and has a strong background in healthcare innovation.

Ben Scruggs, PhD — Partner, also serves as CEO of portfolio company Altis Biosystems, with expertise in biotechnology.

Lauren Flickinger — Partner and Fund Manager of the Pisgah Fund, previously an investment banker at Morgan Stanley.

Christy Shaffer, PhD — General Partner with a focus on biopharmaceuticals and healthcare investments.

Douglas Reed, MD — General Partner with a medical background, enhancing the firm's healthcare investment strategy.

Kim Hodges — CFO and General Partner, overseeing financial operations and fund management.

Fred Goldwater — Venture Partner with extensive experience in healthcare investments.

Holden Thorp — Venture Partner with a strong academic background in health innovation.

Kseniya Simpson, PhD — Principal with expertise in healthcare technology.

Alston Gardner — Special Advisor providing strategic insights.

Parker Johnson — Head of Investor Relations, managing relationships with limited partners.

Graham Smith — Associate involved in deal sourcing and analysis.

Declan Devens — Operations Analyst supporting operational efficiency.

Myla Lai-Goldman, MD — Venture Partner with a focus on medical devices.

Kirkland Hendrickson — Program Manager overseeing various initiatives.

Heather Madsen, PhD — Operating Partner with expertise in healthcare operations.

To pitch Hatteras Venture Partners, founders should prepare a concise pitch deck that includes key information about the business model, market opportunity, and team. The preferred channel for initial contact is through their website or email. Founders should expect a response within a few weeks, and warm introductions are often beneficial.

Hatteras Venture Partners has launched several initiatives to support early-stage healthcare innovation. The **Hatteras Discovery** program focuses on seed-stage projects, allocating up to 20% of certain funds to these opportunities. Additionally, the **Venture Capital Multiplier Fund (VCMF)** is a $60 million fund aimed at co-investing in North Carolina Nexus companies, enhancing the firm's commitment to regional healthcare innovation.

In August 2025, Hatteras Venture Partners closed two new funds, HVP VII and HOF I, raising over $200 million to support healthcare-focused investments. This marks a significant milestone in their ongoing commitment to health innovation.

Recent portfolio activity includes the acquisition of Jumo Health, Inc. in 2024 and Iris Healthcare, Inc. by Aledade in 2023, highlighting the firm's successful exit strategy and active engagement in the healthcare sector.